Literature DB >> 10852123

Immune regulation: susceptibility and resistance to autoimmunity.

D Lo1.   

Abstract

Susceptibility and resistance to autoimmune diabetes appear to be regulated at several levels. Whereas the effector functions of autoimmunity are dependent on the antigen-specific responses of autoreactive T cells, the development of tissue-specific autoimmunity appears to be additionally dependent on tissue-specific factors. Thus, the recruitment of T lymphocytes into the vicinity of islet tissue is driven by the local production of chemokines with a pattern unique to islet tissue. The accumulation of lymphocytes triggers events that lead to the local development of new lymphoid tissue, enhancing the presentation of islet-specific antigens to the immune system. In the presence of additional genetic factors allowing persistent immune responses, autoreactivity is permitted to progress until end-stage autoimmune diabetes develops. My laboratory is studying the influence of tissue-specific factors and the genetic regulation of lymphocyte reactivity. An integrated understanding of these effects should lead to a more physiologic approach to prevention and treatment of autoimmune diabetes.

Entities:  

Mesh:

Year:  2000        PMID: 10852123     DOI: 10.1385/IR:21:2-3:239

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  43 in total

Review 1.  Peripheral tolerance in transgenic mice: tolerance to class II MHC and non-MHC transgene antigens.

Authors:  D Lo; J Freedman; S Hesse; R L Brinster; L Sherman
Journal:  Immunol Rev       Date:  1991-08       Impact factor: 12.988

2.  Thymocytes and RelB-dependent medullary epithelial cells provide growth-promoting and organization signals, respectively, to thymic medullary stromal cells.

Authors:  M Naspetti; M Aurrand-Lions; J DeKoning; M Malissen; F Galland; D Lo; P Naquet
Journal:  Eur J Immunol       Date:  1997-06       Impact factor: 5.532

3.  RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells.

Authors:  L Wu; A D'Amico; K D Winkel; M Suter; D Lo; K Shortman
Journal:  Immunity       Date:  1998-12       Impact factor: 31.745

4.  The density of the class II MHC T cell receptor ligand influences IFN-gamma/IL-4 ratios in immune responses in vivo.

Authors:  L DiMolfetto; H A Neal; A Wu; C Reilly; D Lo
Journal:  Cell Immunol       Date:  1998-01-10       Impact factor: 4.868

5.  Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells.

Authors:  S Tanabe; Z Lu; Y Luo; E J Quackenbush; M A Berman; L A Collins-Racie; S Mi; C Reilly; D Lo; K A Jacobs; M E Dorf
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

6.  Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis.

Authors:  L Fan; C R Reilly; Y Luo; M E Dorf; D Lo
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

7.  Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells.

Authors:  D Lo; J Freedman; S Hesse; R D Palmiter; R L Brinster; L A Sherman
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

8.  Th2-induced eotaxin expression and eosinophilia coexist with Th1 responses at the effector stage of lung inflammation.

Authors:  L Li; Y Xia; A Nguyen; L Feng; D Lo
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

9.  B7 expression on thymic medullary epithelium correlates with epithelium-mediated deletion of V beta 5+ thymocytes.

Authors:  S Degermann; C D Surh; L H Glimcher; J Sprent; D Lo
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

10.  On the various manifestations of spontaneous autoimmune diabetes in rodent models.

Authors:  S Degermann; C Reilly; B Scott; L Ogata; H von Boehmer; D Lo
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.